Compare AbCellera Biologics Inc (ABCL) vs Fubotv Inc (FUBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Fubotv Inc — how do they compare? AbCellera Biologics Inc trades at $7.26 (market cap $2.35B), while Fubotv Inc trades at $9.76 (market cap $290.02M). The key difference: AbCellera Biologics Inc is far larger — about 8.1× Fubotv Inc's market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | FUBO | |
|---|---|---|
Market Cap | $2.35B | $290.02M |
Sector | Health | Technology |
52-Week High | $8.12 | $54.72 |
52-Week Low | $2.78 | $8.09 |
Enterprise Value | $1.99B | $460.44M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
FUBO trades at $9.85, down 3.43% today, with a neutral technical signal. The company shows improving fundamentals with revenue growth to $1.62B in 2024 and projected net income of $123M for 2025, representing a significant turnaround to profitability. Recent developments include streaming partnerships with NBCUniversal and the BIG3 basketball league, while analyst consensus remains positive with a $16.25 price target.
FUBO presents a compelling turnaround story with improving profitability metrics and strong analyst support, though negative cash flow and high debt levels pose execution risks. The stock offers substantial upside potential if the company can maintain its path to sustainable profitability through content partnerships and advertising growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →
